Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

Javier Ros-Montañá,Giulia Martini,Iosune Baraibar,Guillermo Villacampa,Raquel Comas,D. Ciardiello,Ariadna Garcia,Xavier Hernández-Yagüe,Bernardo Queralt,Antonieta Salud-Salvia,Guillem Argiles,Jose Luis Cuadra,Rodrigo A. Toledo,Irene Chicote,Nuria Mulet,Ana Vivancos,Héctor G. Pálmer,Rodrigo Dienstmann,Josep Tabernero,Elena Elez

Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

2020

4112Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- ME...

Keywords:

Internal medicine
Colorectal cancer
Oncology
overall survival
Targeted therapy
Pathology
Medicine
Mutant
aggressive disease
BRAF inhibitor
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations